DavidJohnKuterMDDRPHIL

PubMed

• 122 citations
  Thrombopoietin and Thrombopoietin Mimetics in the Treatment of Thrombocytopenia
  David J. Kuter
  Annual Review of Medicine. 2009-03-25
• 13 citations
  Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-...
  Catherine M Broome, Vickie McDonald, Yoshitaka Miyakawa, Monica Carpenedo, David J Kuter
  Lancet. 2023-11-04
• 2074 citations
  A phase 2 study of bortezomib in relapsed, refractory myeloma.
  Paul G. Richardson, Bart Barlogie, James R. Berenson, Seema Singhal, Sundar Jagannath
  The New England Journal of Medicine. 2003-06-26

Journal Articles

• Romiplostim in Adult Patients with Newly Diagnosed or Persistent Immune Thrombocytopenia (ITP) for up to 1 Year and in Those with Chronic ITP for More Than 1 Year: A S...  
  David J Kuter, Bhakti Mehta, British Journal of Haematology
• Presenting Signs and Patient Co‐Variables in Gaucher Disease: Outcome of the Gaucher Early Diagnosis Consensus (GED‐C) Delphi Initiative  
  David J Kuter, Neal J Weinreb, Internal Medicine Journal

Abstracts/Posters

• Phase 2 Study of Efgartigimod, a Novel FcRn Antagonist, in Adult Patients with Primary Immune Thrombocytopenia
  David J. Kuter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

• Avatrombopag, an Oral Thrombopoietin Receptor Agonist: Results of Two Double‐Blind, Dose‐Rising, Placebo‐Controlled Phase 1 Studies 
  American Thoracic Society, 2013 International Conference, Philadelphia, Pennsylvania, USA
• Avatrombopag, an Oral Thrombopoietin Receptor Agonist: Results of Two Double‐Blind, Dose‐Rising, Placebo‐Controlled Phase 1 Studies 
  2013 International Conference, Philadelphia, Pennsylvania, USA
• Aware of the Rare: Diagnosing and Treating Immune-Mediated Hematologic Disorders 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Antiplatelet Antibody Testing in Immune Thrombocytopenia and Evans Syndrome: Longitudinal Serologic Evolution and Relation to Clinical Features 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Infections and Vaccination in Hereditary Hemorrhagic Telangiectasia: Microbiological Evidence-Based Considerations 
  Harvard Medical School, Boston, Massachusetts - 9/30/2012
• Infections and Vaccination in Hereditary Hemorrhagic Telangiectasia: Microbiological Evidence-Based Considerations 
  Harvard Medical School ,Department Of Continuing Education, Cambridge, Massachusetts - 6/10/2013
• Join now to see all

Other

• Infections and Vaccination in Hereditary Hemorrhagic Telangiectasia: Microbiological Evidence-Based Considerations 
  David Kuter, MD, Haematologica
  https://www.doximity.com/articles/316713ed-d3e2-47da-8487-94d0db6754ab
  UpToDate, Wolters Kluwer Health - 2012-07-24
• Infections and Vaccination in Hereditary Hemorrhagic Telangiectasia: Microbiological Evidence-Based Considerations 
  David Kuter, MD, Haematologica
  https://www.doximity.com/articles/316713ed-d3e2-47da-8487-94d0db6754ab
  UpToDate, Wolters Kluwer Health - 2013-01-30
• Avatrombopag, an Oral Thrombopoietin Receptor Agonist: Results of Two Double‐Blind, Dose‐Rising, Placebo‐Controlled Phase 1 Studies 
  David Kuter, MD, British Journal of Haematology
  https://www.doximity.com/articles/d909d298-5043-4c91-b3f6-84a999dd1fef
  UpToDate, Wolters Kluwer Health - 2012-09-07